Glucotrack (Nasdaq:GCTK) announced today that it secured a bridge financing to support the completion of its merger with Lōkahi Therapeutics. The bridge financing, designed to support their strategic growth objectives, allows for the completion of the combination to proceed. Glucotrack did not disclose the terms of the financing. Earlier this week, the company’s announced their […]
Mergers & Acquisitions
Glucotrack combines with Lōkahi Therapeutics to become CBGM subsidiary
Glucotrack (Nasdaq:GCTK) announced that it completed a strategic business combination with Lōkahi Therapeutics. The companies structured the combination so that Lōkahi becomes the operating and controlling business of the combined company. It now leverages Glucotrack’s continuous blood glucose monitoring (CBGM) business as a wholly owned subsidiary. According to a news release, the combined organization integrates […]
West completes sale of on-body drug delivery device to AbbVie
West Pharmaceutical Services (NYSE:WST) announced that it completed the sale of its SmartDose on-body delivery system to AbbVie. Exton, Pennsylvania-based West sold and transferred its manufacturing and supply rights for the SmartDose 3.5mL on-body delivery system and associated facilities to AbbVie. The companies closed their transaction, as planned, on July 1, 2026. West will continue […]
ALR Technologies acquires Singapore-based CGM maker for $45M
ALR Technologies announced today that it entered into a letter of intent to acquire equity and assets of CGM Medical Technology. The Singapore-based company agreed to acquire 100% equity of CGM Medical Technology Singapore and assets of CGM Medical Technology Shenzhen. Its deal includes an aggregate purchase price of 200 million ordinary shares and $45 […]
Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
Dexcom (Nasdaq:DXCM) announced today that entered into an agreement to acquire Nutrisense and shared plans for upgrades to its Stelo sensor. San Diego-based Dexcom expects its deal to buy Nutrisense for an undisclosed amount in the coming weeks. With the acquisition, the continuous glucose monitor (CGM) maker plans to further expand its ability to support […]
Embecta completes Owen Mumford acquisition
Embecta (Nasdaq:EMBC) announced that it completed its previously announced acquisition of Owen Mumford Holdings Limited. Parsippany, New Jersey-based Embecta completed the deal on Friday, May 15. The former BD Diabetes business agreed to acquire Owen Mumford in March. The deal includes an upfront cash payment of approximately $133 million (£100 million). It also includes an […]
Embecta to acquire auto-injector maker Owen Mumford for up to $199.4M
Embecta (Nasdaq:EMBC) announced today that it entered into a definitive agreement to acquire Owen Mumford Holdings Limited. Owen Mumford, a privately held, UK-based company, develops and manufactures medical devices and drug delivery technologies. Embecta, the former BD Diabetes business, agreed to acquire Owen Mumford with an upfront cash payment of approximately $133 million (£100 million). […]
West sells manufacturing, supply rights for on-body drug delivery system to AbbVie
West Pharmaceutical Services (NYSE:WST) announced that it reached an agreement to sell on-body drug delivery technology to AbbVie. The company agreed to sell all manufacturing and supply rights for the SmartDose 3.5mL on-body system and associated facilities. Exton, Pennsylvania-based West said the deal includes a total consideration of $112.5 million at close. It expects the […]
Sequel twiist developer DEKA acquires assets, IP from Diatech Diabetes
Diatech Diabetes announced today that DEKA Research & Development acquired its core assets and intellectual property (IP). DEKA, the firm behind the Sequel Med Tech twiist automated insulin delivery system, developed the underlying drug delivery technology for the recently launched pump. Dean Kamen, co-founder of Sequel and founder of DEKA, commercialized the first wearable insulin […]
Elutia closes $88M bioenvelope sale to Boston Scientific
Elutia (Nasdaq:ELUT) announced today that it closed the $88 million sale of its bioenvolope technologies to Boston Scientific. Last month, the Gaithersburg, Maryland-based company announced an agreement to sell its EluPro and CanGaroo drug-eluting bioenvelopes to Boston Scientific in an all-cash deal. It designed these technologies to protect patients receiving implantable medical devices. With the […]
